Recent advances in first-line treatment of metastatic colorectal cancer

摘要

That would have to be CRYSTAL, PRIME and COIN trials for setting some guidance on the use of anti-EGF receptor (EGFR) therapy in the first-line setting. The PRIME and COIN studies suggest a modest improvement in response rate (RR) and progression-free survival (PFS) with the addition of panitumumab or cetuximab to combined folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) chemotherapy (COIN and PRIME) in KRAS wild-type (WT) tumors.